U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C18H26FN3O6
Molecular Weight 399.4139
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MERICITABINE

SMILES

CC(C)C(=O)OC[C@H]1O[C@@H](N2C=CC(N)=NC2=O)[C@](C)(F)[C@@H]1OC(=O)C(C)C

InChI

InChIKey=MLESJYFEMSJZLZ-MAAOGQSESA-N
InChI=1S/C18H26FN3O6/c1-9(2)14(23)26-8-11-13(28-15(24)10(3)4)18(5,19)16(27-11)22-7-6-12(20)21-17(22)25/h6-7,9-11,13,16H,8H2,1-5H3,(H2,20,21,25)/t11-,13-,16-,18-/m1/s1

HIDE SMILES / InChI

Molecular Formula C18H26FN3O6
Molecular Weight 399.4139
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Mericitabine is a specific inhibitor of hepatitis C virus (HCV) replication that target NS5B polymerase. Mericitabine, a prodrug, is hydrolyzed in vivo to produce PSI-6130. It had been studied in phase II clinical trials for the treatment of chronic hepatitis C. However, while it showed a good safety profile in clinical trials, it was not sufficiently effective to be used as a standalone agent.

Approval Year

Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
0.557 μg/mL
1000 mg single, oral
dose: 1000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RO5012433 plasma
Homo sapiens
population: HEALTHY
age: ADOLESCENT
sex: FEMALE / MALE
food status: FASTED
0.854 μg/mL
2000 mg single, oral
dose: 2000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RO5012433 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
0.361 μg/mL
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RO5012433 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
10.2 μg/mL
2000 mg single, oral
dose: 2000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RO4995855 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
4.23 μg/mL
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RO4995855 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
11.2 μg × h/mL
1000 mg single, oral
dose: 1000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RO5012433 plasma
Homo sapiens
population: HEALTHY
age: ADOLESCENT
sex: FEMALE / MALE
food status: FASTED
20.5 μg × h/mL
2000 mg single, oral
dose: 2000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RO5012433 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
6.35 μg × h/mL
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RO5012433 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
113 μg × h/mL
2000 mg single, oral
dose: 2000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RO4995855 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
28.8 μg × h/mL
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RO4995855 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
22.7 h
1000 mg single, oral
dose: 1000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RO5012433 plasma
Homo sapiens
population: HEALTHY
age: ADOLESCENT
sex: FEMALE / MALE
food status: FASTED
21.8 h
2000 mg single, oral
dose: 2000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RO5012433 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
19 h
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RO5012433 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
5.54 h
2000 mg single, oral
dose: 2000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RO4995855 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
4.96 h
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RO4995855 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Tetrazole and triazole as bioisosteres of carboxylic acid: discovery of diketo tetrazoles and diketo triazoles as anti-HCV agents.
2013 Aug 15
Highly efficient infectious cell culture of three hepatitis C virus genotype 2b strains and sensitivity to lead protease, nonstructural protein 5A, and polymerase inhibitors.
2014 Feb
The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance.
2014 Jun
Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies.
2016
Modelling the interaction between danoprevir and mericitabine in the treatment of chronic HCV infection.
2016
Ritonavir-boosted danoprevir-based regimens in treatment-naive and prior null responders with HCV genotype 1 or 4 and compensated cirrhosis.
2016 May
Patents

Sample Use Guides

1500 mg doses twice daily for 2 weeks
Route of Administration: Oral
A stable HCV 1b replicon cell (Gt 1b Con1) line was treated with the NS5B nucleoside inhibitor R7128 (prodrug PSI-6130). Inhibition of HCV replicon-encoded Renilla luciferase reporter activity after 3 days of incubation was calculated - EC50 = 0.61 uM.
Substance Class Chemical
Created
by admin
on Fri Dec 15 19:41:09 UTC 2023
Edited
by admin
on Fri Dec 15 19:41:09 UTC 2023
Record UNII
TA63JX8X52
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MERICITABINE
INN   USAN   WHO-DD  
USAN   INN  
Official Name English
R-7128
Code English
2'-DEOXY-2'-FLUORO-2'-C-METHYLCYTIDINE DIISOBUTYRATE
Common Name English
mericitabine [INN]
Common Name English
RG7128
Code English
RO-5024048
Code English
MERICITABINE [USAN]
Common Name English
PSI6130 DIISOBUTYRATE
Code English
Mericitabine [WHO-DD]
Common Name English
RO5024048
Code English
CYTIDINE, 2'-DEOXY-2'-FLUORO-2'-METHYL-, 3',5'-BIS(2-METHYLPROPANOATE), (2'R)-
Common Name English
3',5'-DIISOBUTYRYL PSI6130
Code English
R7128
Code English
2'.ALPHA.-FLUORO-2'.BETA.-METHYL-3',5'-DIISOBUTYRYLDEOXYCYTIDINE
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C281
Created by admin on Fri Dec 15 19:41:09 UTC 2023 , Edited by admin on Fri Dec 15 19:41:09 UTC 2023
NCI_THESAURUS C1557
Created by admin on Fri Dec 15 19:41:09 UTC 2023 , Edited by admin on Fri Dec 15 19:41:09 UTC 2023
Code System Code Type Description
EVMPD
SUB89593
Created by admin on Fri Dec 15 19:41:09 UTC 2023 , Edited by admin on Fri Dec 15 19:41:09 UTC 2023
PRIMARY
PUBCHEM
16122663
Created by admin on Fri Dec 15 19:41:09 UTC 2023 , Edited by admin on Fri Dec 15 19:41:09 UTC 2023
PRIMARY
EPA CompTox
DTXSID201025655
Created by admin on Fri Dec 15 19:41:09 UTC 2023 , Edited by admin on Fri Dec 15 19:41:09 UTC 2023
PRIMARY
FDA UNII
TA63JX8X52
Created by admin on Fri Dec 15 19:41:09 UTC 2023 , Edited by admin on Fri Dec 15 19:41:09 UTC 2023
PRIMARY
DRUG BANK
DB12045
Created by admin on Fri Dec 15 19:41:09 UTC 2023 , Edited by admin on Fri Dec 15 19:41:09 UTC 2023
PRIMARY
USAN
ZZ-121
Created by admin on Fri Dec 15 19:41:09 UTC 2023 , Edited by admin on Fri Dec 15 19:41:09 UTC 2023
PRIMARY
SMS_ID
100000140218
Created by admin on Fri Dec 15 19:41:09 UTC 2023 , Edited by admin on Fri Dec 15 19:41:09 UTC 2023
PRIMARY
NCI_THESAURUS
C98959
Created by admin on Fri Dec 15 19:41:09 UTC 2023 , Edited by admin on Fri Dec 15 19:41:09 UTC 2023
PRIMARY
CAS
940908-79-2
Created by admin on Fri Dec 15 19:41:09 UTC 2023 , Edited by admin on Fri Dec 15 19:41:09 UTC 2023
PRIMARY
ChEMBL
CHEMBL562967
Created by admin on Fri Dec 15 19:41:09 UTC 2023 , Edited by admin on Fri Dec 15 19:41:09 UTC 2023
PRIMARY
INN
9293
Created by admin on Fri Dec 15 19:41:09 UTC 2023 , Edited by admin on Fri Dec 15 19:41:09 UTC 2023
PRIMARY
WIKIPEDIA
Mericitabine
Created by admin on Fri Dec 15 19:41:09 UTC 2023 , Edited by admin on Fri Dec 15 19:41:09 UTC 2023
PRIMARY
Related Record Type Details
TARGET ORGANISM->INHIBITOR
TARGET -> INHIBITOR
Related Record Type Details
METABOLITE ACTIVE -> PRODRUG
Related Record Type Details
ACTIVE MOIETY